European Medicines Agency executive director Professors Guido Rasi’s tenure in the post has had its dramatic moments, since the annulment of his 2011 appointment in 2014 after allegations that the recruitment procedure had been wrong by Emil Hristov, a former top Bulgarian drug regulator, who applied for the job but was left off the shortlist.
He made a comeback in 2015, but there was still a question mark over Prof Rasi’s declaration of interests, which last week was also clarified by a ruling from the European Ombudsman, concluding that there had been no maladministration at the EMA.
In a press statement on Friday, the EMA said it welcomes the decision by the European Ombudsman, Emily O’Reilly, that there was no maladministration in its handling of the declaration of interests of its executive director.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze